Getting to Know the Facts About Apellis Pharmaceuticals

Mid-cap Health Care company Apellis Pharmaceuticals logged a 2.3% change Friday on a trading volume of 1,265,892. The average volume for the stock is 1,808,722.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Based in Waltham, United States the company has 767 full time employees and a market cap of $9,009,006,592.

The company is now trading -6.23% away from its average analyst target price of $86.33 per share. The 15 analysts following the stock have set target prices ranging from $51.0 to $139.0, and on average give Apellis Pharmaceuticals a rating of buy.

Over the last year, APLS shares have gone up 57.4%, which represents a difference of 63.0% when compared to the S&P 500. The stock's 52 week high is $81.3 per share whereas its 52 week low is $33.32. Based on Apellis Pharmaceuticals's average operating margin growth of 100.0% over the last four years, its core business remains strong and its strong stock performance may continue in the long term.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.